Thermo Fisher bags single-use bioreactor tech partner Finesse

By Dan Stanton contact

- Last updated on GMT

Image: iStock/designer491
Image: iStock/designer491

Related tags: Thermo fisher, Life, Technology, Biology

Thermo Fisher Scientific says it is buying Finesse Solutions, its long-term supplier of measurement and control solutions for bioprocessing applications.

The deal announced yesterday, adds bioprocess management technology Finesse Solutions to Thermo Fisher’s life sciences business.

CEO Marc Casper said the Santa Clara, California-based firm has been a technology partner since 2013, and its universal control system which combines with Thermo Fisher’s own single-use technologies will “strengthen our position in the high-growth bioproduction market.”

Finesse’s Smart technology suite offers a range of data management software, and bioreactor controllers and sensors which allow bioprocessing firms and drugmakers to configurate biomanufacturing processes from labscale to cGMP-compliant production.

Finesse generated around $50m in revenue last year. Financial details of the deal were not divulged, but Thermo Fisher expects the deal to close in the next few days, having received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.


The deal is the latest in a string of acquisitions made in the life science space by Thermo Fisher.

Last year the firm bought biological analysis firm Affymetrix​ for $1.3bn, analytical instrument firm FEI Company​ for $4.2bn, and stem cell tech and reagent business MTI-GlobalStem​. 2015 saw the company add disposable technology firm ASI to its bioprocessing arsenal for $300m, and a year earlier Life Technologies​ was acquired for $13bn.

Thermo Fisher was also rumoured to be interested in buying downstream disposable tech firm Pall Corporation – since acquired by Danaher for $13bn​ – and last summer was allegedly eyeing up Illumina for $30bn​.

During a call to discuss its Q4 results late last month, Casper told investors his firm continued to look at a number of M&A opportunities.

“The industry is incredibly fragmented,”​ he said. “So we follow our strategy of looking at things that will strengthen the company strategically, clearly be understood and valued by our customers and create shareholder value, with the primary metric being return on invested capital.”

Related news

Show more

Related products

show more

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more